Palisade Bio, Inc. (NASDAQ:PALI) Short Interest Update

Palisade Bio, Inc. (NASDAQ:PALI) saw a significant decline in short interest in January. As of January 15th, there was short interest totalling 66,300 shares, a decline of 96.4% from the December 31st total of 1,840,000 shares. Approximately 2.4% of the shares of the stock are short sold. Based on an average trading volume of 1,270,000 shares, the short-interest ratio is currently 0.1 days.

Palisade Bio Stock Down 4.7 %

Shares of PALI opened at $1.43 on Thursday. Palisade Bio has a 1-year low of $1.33 and a 1-year high of $11.75. The firm’s 50 day simple moving average is $1.86 and its 200 day simple moving average is $2.93.

Palisade Bio (NASDAQ:PALI) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($2.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.35) by $1.03. On average, sell-side analysts anticipate that Palisade Bio will post -12.43 EPS for the current year.

Wall Street Analysts Forecast Growth

PALI has been the topic of several recent analyst reports. Brookline Capital Management started coverage on shares of Palisade Bio in a research note on Wednesday, November 20th. They issued a “buy” rating and a $38.00 target price on the stock. Maxim Group decreased their price target on shares of Palisade Bio from $22.50 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th.

Institutional Trading of Palisade Bio

An institutional investor recently bought a new position in Palisade Bio stock. JPMorgan Chase & Co. bought a new stake in shares of Palisade Bio, Inc. (NASDAQ:PALI) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 8,200 shares of the company’s stock, valued at approximately $29,000. JPMorgan Chase & Co. owned 0.54% of Palisade Bio at the end of the most recent reporting period. 11.79% of the stock is owned by hedge funds and other institutional investors.

Palisade Bio Company Profile

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.